Skip to main content
GutCited

Beschreibung

Multi-panel analysis results labeled (c) and (d) from the synbiotic IBS-D trial present additional symptom domain comparisons.

Figure 22

Chart

Source Paper

The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant …

Nutrients (2020)

PMID: 32635661

DOI: 10.3390/nu12071999

Cite This Figure

![Figure 22: Multi-panel analysis results labeled (c) and (d) from the synbiotic IBS-D trial present additional symptom domain comparisons.]()

> Source: Barbara Skrzydło-Radomańska et al. "The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidoba." *Nutrients*, 2020. PMID: [32635661](https://pubmed.ncbi.nlm.nih.gov/32635661/)
<figure>
  <img src="" alt="Multi-panel analysis results labeled (c) and (d) from the synbiotic IBS-D trial present additional symptom domain comparisons." />
  <figcaption>Figure 22. Multi-panel analysis results labeled (c) and (d) from the synbiotic IBS-D trial present additional symptom domain comparisons.<br>  Source: Barbara Skrzydło-Radomańska et al. "The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidoba." <em>Nutrients</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32635661/">32635661</a></figcaption>
</figure>

Verwandte Evidenz

B
Bifidobacterium longum für Irritable Bowel Syndrome (IBS)

Bewertung B · 4 Studien

 B
Galactooligosaccharides (GOS) für Irritable Bowel Syndrome (IBS)

Bewertung B · 3 Studien

 B
Lactobacillus acidophilus für Irritable Bowel Syndrome (IBS)

Bewertung B · 3 Studien

 D
Fructooligosaccharides (FOS) für Irritable Bowel Syndrome (IBS)

Bewertung D · 2 Studien